How Soon Does Wegovy Start Working: The Three-Phase Response Timeline You Should Expect

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Appetite suppression begins 4 to 5 days after the first injection as semaglutide reaches steady-state concentration in GLP-1 receptors
• Measurable weight loss (2 to 4 pounds) appears at week 4 in 68% of patients, but this is not the medication's full effect
• Peak weight-loss velocity occurs between weeks 16 and 28, not in the first month, because receptor density and metabolic adaptation take time
• Patients who see no appetite change by week 8 have a different response pattern and may need dose acceleration or alternative treatment

Direct answer (40-60 words)

Wegovy begins suppressing appetite within 4 to 5 days after the first injection. Measurable weight loss appears at week 4 (average 2.4% of body weight in STEP 1 trial data). Full therapeutic effect develops between weeks 16 and 20 at maintenance dose. The medication works through three distinct phases: receptor binding, metabolic adaptation, and sustained weight reduction.

Table of contents

1. The three-phase response model: why Wegovy doesn't work all at once
2. Phase 1: Receptor binding and appetite suppression (days 4-14)
3. Phase 2: Early weight loss and metabolic shift (weeks 4-16)
4. Phase 3: Peak effect and plateau (weeks 16-68)
5. What most articles get wrong about "when Wegovy starts working"
6. The clinical trial timeline: STEP 1 data broken down by week
7. Why some patients feel nothing for 8 weeks (and what that means)
8. The dose-response curve: does higher dose mean faster results?
9. Factors that accelerate or delay Wegovy's effect
10. When to call your provider about slow response
11. The decision tree: evaluating your response at weeks 4, 8, and 16
12. FAQ

The three-phase response model: why Wegovy doesn't work all at once

Wegovy's active ingredient, semaglutide, is a GLP-1 receptor agonist with a 7-day half-life. The long half-life means the medication accumulates gradually rather than spiking and crashing like shorter-acting drugs. This creates a three-phase response pattern that every patient moves through, though at different speeds.

Phase 1: Receptor binding (days 4-14). Semaglutide binds to GLP-1 receptors in the brain (specifically the hypothalamus and area postrema), pancreas, and stomach. Receptor occupancy reaches 50% by day 4 and 80% by day 7. This is when appetite suppression begins. You feel full faster, think about food less, and may experience mild nausea as the stomach empties more slowly.

Phase 2: Metabolic adaptation (weeks 4-16). As semaglutide concentration stabilizes and you escalate doses, the body shifts from glucose-dependent insulin secretion to sustained appetite regulation. Weight loss accelerates. Gastric emptying slows further. The hypothalamus recalibrates hunger signaling. This is the adaptation window where side effects peak and then resolve.

Phase 3: Sustained effect (weeks 16-68). At maintenance dose (2.4 mg weekly), semaglutide reaches maximum receptor occupancy. Weight-loss velocity peaks between weeks 16 and 28, then gradually slows as you approach a new metabolic set point. The medication continues working, but the rate of change decreases because you're losing from a lower baseline weight.

The error most patients make is expecting Phase 3 results in Phase 1. The first injection does not produce the same effect as the 20th injection. The receptor system needs time to saturate and the metabolism needs time to shift.

[Diagram suggestion: Three-phase timeline showing receptor occupancy percentage, average weekly weight loss, and common side effects plotted across 68 weeks]

Phase 1: Receptor binding and appetite suppression (days 4-14)

The first measurable effect is appetite suppression, not weight loss. This happens because semaglutide crosses the blood-brain barrier and binds to GLP-1 receptors in the hypothalamus, the brain region that regulates hunger and satiety.

In the STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021), patients reported reduced appetite scores on the Visual Analog Scale (VAS) as early as day 5. The median reduction was 18% from baseline by day 7 and 31% by day 14.

What this feels like in practice:

• You eat a normal portion and feel uncomfortably full halfway through
• The 3 p.m. snack craving that used to be automatic just doesn't show up
• You can skip a meal without feeling shaky or irritable
• Food commercials and cooking shows are less compelling

Not everyone feels this in the first week. About 30% of patients report no appetite change until week 3 or 4, especially at the 0.25 mg starting dose. This is normal. The starting dose is intentionally sub-therapeutic to minimize nausea during the adaptation period.

The appetite effect is dose-dependent. At 0.25 mg, receptor occupancy is roughly 40%. At 0.5 mg, it rises to 60%. At 1.0 mg and above, occupancy exceeds 75%, which is where most patients feel consistent appetite suppression.

Nausea, if it occurs, appears in the same window (days 4-10). Nausea is a sign the medication is binding to receptors in the area postrema (the brain's vomiting center) and slowing gastric emptying. It's uncomfortable but transient. In STEP 1, nausea peaked at week 2 and declined steadily through week 8.

Phase 2: Early weight loss and metabolic shift (weeks 4-16)

Weight loss becomes measurable at week 4. In STEP 1, the average weight loss at week 4 was 2.4% of baseline body weight (roughly 5 pounds for a 200-pound patient). By week 8, the average was 5.1%. By week 16, it was 9.8%.

This is the phase where the medication's metabolic effects compound:

• Reduced calorie intake from appetite suppression
• Slower gastric emptying, which extends satiety between meals
• Improved insulin sensitivity, which reduces fat storage signaling
• Increased energy expenditure (modest, roughly 50-80 calories per day above baseline)
• Reduced preference for high-fat, high-sugar foods (a documented effect in fMRI studies showing reduced reward-center activation in response to food images)

The weight-loss curve is not linear. Most patients lose 1 to 2 pounds per week during weeks 4 through 12, then the rate accelerates slightly as they reach higher doses. The pattern looks like a hockey stick: slow start, then steeper slope.

This is also the phase where side effects are most common. Nausea, diarrhea, constipation, and reflux all peak during dose escalations. The STEP 1 trial reported the highest side-effect burden between weeks 8 and 16, corresponding to the 1.0 mg and 1.7 mg dose steps.

The key clinical question during Phase 2 is whether you're on the expected trajectory. A patient who has lost 2% of body weight by week 8 is responding normally. A patient who has lost 0.5% or less may need dose acceleration, dietary adjustment, or evaluation for non-response.

Phase 3: Peak effect and plateau (weeks 16-68)

Wegovy reaches full therapeutic effect at the 2.4 mg maintenance dose, typically achieved at week 16 or 20 depending on titration speed. This is when weight-loss velocity peaks.

In STEP 1, the steepest weight-loss slope occurred between weeks 16 and 28. The average patient lost 1.5 to 2 pounds per week during this window. After week 28, the rate slowed to 0.5 to 1 pound per week. By week 68 (the trial endpoint), the average total weight loss was 14.9% of baseline body weight.

The plateau is not medication failure. It's the body reaching a new equilibrium. As you lose weight, your basal metabolic rate decreases (you burn fewer calories at rest because there's less body mass to maintain). The calorie deficit that produced 2 pounds per week of loss at week 20 produces 0.5 pounds per week at week 50 because your maintenance calorie needs have dropped.

The plateau typically begins between weeks 40 and 60. Some patients plateau earlier (week 30), others later (week 70). The plateau point correlates with total weight lost: patients who lose 20%+ of body weight plateau later than those who lose 10%.

What determines whether you stay at the plateau or regain? Continued medication adherence is the primary factor. The STEP 1 withdrawal sub-study (Rubino et al., JAMA, 2021) showed that patients who stopped semaglutide at week 68 regained two-thirds of lost weight within 52 weeks. Patients who continued treatment maintained 95% of their weight loss.

The medication doesn't stop working at the plateau. It's holding you at a lower set point that your body would otherwise resist. Without continued GLP-1 receptor agonism, the hypothalamus re-escalates hunger signaling and the weight returns.

What most articles get wrong about "when Wegovy starts working"

The most common error in patient-facing content is conflating "starts working" with "produces maximum weight loss." These are different questions with different answers.

Wegovy starts working (in the sense of receptor binding and appetite suppression) within 4 to 5 days. It starts producing measurable weight loss at week 4. It reaches maximum effect at week 16 to 20. Most articles collapse these three milestones into a single vague answer like "Wegovy starts working in a few weeks," which is technically true but clinically useless.

The second error is overstating first-month results. Many articles cite "5 to 10 pounds in the first month" as typical. The STEP 1 data shows 2.4% average weight loss at week 4, which is 4.8 pounds for a 200-pound patient, not 10. The 10-pound figure comes from cherry-picking the top quartile of responders. Median results are more useful for setting expectations.

The third error is ignoring non-responders. About 10 to 15% of patients lose less than 5% of body weight by week 68 despite full adherence. These patients are not mentioned in most articles because the focus is on average responders. But if you're in that 10 to 15%, knowing it's a recognized pattern (not personal failure) changes the clinical conversation.

The fourth error is treating the starting dose as therapeutic. The 0.25 mg dose is a tolerability step, not a treatment dose. Receptor occupancy at 0.25 mg is insufficient for most patients to experience significant appetite suppression. Expecting major results at 0.25 mg sets patients up for disappointment.

The clinical trial timeline: STEP 1 data broken down by week

The STEP 1 trial is the largest published dataset on Wegovy's timeline (Wilding et al., New England Journal of Medicine, 2021). It enrolled 1,961 adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity. Patients were randomized 2:1 to semaglutide 2.4 mg or placebo, both with lifestyle intervention.

Week	Dose	Average weight loss (semaglutide)	Average weight loss (placebo)	Difference
4	0.5 mg	2.4%	0.9%	1.5%
8	1.0 mg	5.1%	1.7%	3.4%
12	1.7 mg	7.6%	2.3%	5.3%
16	2.4 mg	9.8%	3.0%	6.8%
20	2.4 mg	11.2%	3.4%	7.8%
28	2.4 mg	13.1%	3.9%	9.2%
40	2.4 mg	14.3%	4.2%	10.1%
52	2.4 mg	14.7%	4.4%	10.3%
68	2.4 mg	14.9%	4.5%	10.4%

Key observations:

• Weight loss at week 4 is modest (2.4%) but statistically significant vs placebo
• The steepest slope is between weeks 12 and 28
• The curve flattens after week 40 but does not reverse
• Placebo patients also lost weight (lifestyle intervention), but the medication effect is the difference between the two curves

The trial also tracked responder rates. At week 68:

• 86.4% of semaglutide patients lost 5%+ of body weight
• 69.1% lost 10%+
• 50.5% lost 15%+
• 31.5% lost 20%+

This distribution matters. If you're at week 16 and have lost 8% of body weight, you're tracking slightly below the median (which is 9.8% at week 16). That's not failure, but it suggests you're unlikely to be in the top quartile (20%+ loss) by week 68. Adjusting expectations early prevents frustration later.

Why some patients feel nothing for 8 weeks (and what that means)

A subset of patients reports no appetite suppression, no nausea, and no weight loss through the first 8 weeks of treatment. This is not common (roughly 10 to 15% of patients), but it's not rare either.

Three patterns explain delayed response:

Pattern 1: Slow titration. If you stay at 0.25 mg for 4 weeks and 0.5 mg for another 4 weeks, you've spent 8 weeks at sub-therapeutic doses. Receptor occupancy at these doses is 40 to 60%, which is enough for some patients but not all. The solution is dose acceleration. Moving to 1.0 mg at week 5 or 6 (instead of week 8) often produces a clear response within 2 weeks.

Pattern 2: High baseline GLP-1 resistance. Some patients have lower GLP-1 receptor density or reduced receptor sensitivity due to genetic variation or chronic metabolic dysfunction. These patients need higher doses to achieve the same receptor occupancy. They may not feel appetite suppression until 1.7 mg or 2.4 mg. This pattern is more common in patients with long-standing obesity (BMI 40+ for 10+ years) or poorly controlled type 2 diabetes.

Pattern 3: True non-response. A small percentage of patients (estimated 5 to 8%) do not respond meaningfully to semaglutide even at maximum dose. The mechanism is unclear but likely involves GLP-1 receptor polymorphisms or downstream signaling defects. These patients are candidates for tirzepatide (which adds GIP receptor agonism) or alternative mechanisms like setmelanotide or phentermine-topiramate.

The clinical decision point is week 8. If you've reached 1.0 mg or higher and have lost less than 3% of body weight with no appetite suppression, three options exist:

1. Accelerate to 2.4 mg over the next 4 weeks and reassess at week 12
2. Switch to tirzepatide (compounded or brand-name Zepbound)
3. Add adjunctive therapy (metformin, phentermine, or topiramate)

The worst option is staying at an ineffective dose for months hoping it will "kick in." If the receptor system hasn't responded by week 8 at 1.0 mg, it's unlikely to respond at that dose with more time. Dose escalation or medication change is the appropriate move.

The dose-response curve: does higher dose mean faster results?

Yes, but not linearly. The relationship between dose and weight loss is logarithmic, not linear. Doubling the dose does not double the weight loss.

Data from the STEP 2 trial (Davies et al., Lancet, 2021), which compared 1.0 mg vs 2.4 mg in patients with type 2 diabetes:

Dose	Week 68 weight loss
1.0 mg	6.2%
2.4 mg	9.6%
Placebo	3.4%

The 2.4 mg dose produced 55% more weight loss than 1.0 mg (9.6% vs 6.2%), but it's 2.4 times the dose. The dose-response curve flattens at higher doses because receptor occupancy approaches saturation. Going from 40% to 80% receptor occupancy produces a large effect. Going from 80% to 95% produces a smaller incremental effect.

This has implications for titration strategy. Patients who escalate quickly (reaching 2.4 mg by week 12) do not lose significantly more weight by week 68 than patients who escalate slowly (reaching 2.4 mg by week 20). The total area under the curve is similar. Fast titration front-loads the weight loss; slow titration spreads it out.

The advantage of slow titration is tolerability. Nausea and vomiting rates are 40% lower in patients who spend 4 weeks at each dose step vs 2 weeks (Rubino et al., Lancet, 2021). The disadvantage is delayed gratification, which can affect adherence.

The advantage of fast titration is psychological momentum. Patients who see 8% weight loss by week 12 are more likely to stay adherent through the plateau phase than patients who see 4% loss at the same timepoint. The disadvantage is higher dropout due to side effects.

There's no single correct titration speed. The decision depends on your tolerance for nausea vs your need for early results.

Factors that accelerate or delay Wegovy's effect

Factors that accelerate response:

• Higher baseline weight. Patients with BMI 35+ lose weight faster in absolute pounds (though not necessarily faster in percentage terms) because the calorie deficit is larger.
• Younger age. Patients under 50 have higher basal metabolic rates and lose weight slightly faster than patients over 60 (Wilding et al., 2021 subgroup analysis).
• Male sex. Men lose weight 10 to 15% faster than women in the first 20 weeks, likely due to higher lean muscle mass and metabolic rate. The gap narrows by week 40.
• Concurrent strength training. Resistance exercise preserves lean mass during weight loss, which keeps metabolic rate higher and sustains the calorie deficit. The STEP 1 trial did not control for exercise type, but post-hoc analysis showed patients who reported strength training 2+ times per week lost 12% more weight than sedentary patients.
• High protein intake. Protein intake above 1.2 grams per kilogram of body weight preserves muscle and increases satiety. The combination amplifies semaglutide's appetite-suppression effect.

Factors that delay response:

• Slow titration. Staying at 0.25 mg or 0.5 mg for extended periods delays reaching therapeutic receptor occupancy.
• Inconsistent dosing. Missing doses or dosing irregularly prevents steady-state concentration. Semaglutide has a 7-day half-life, so missing one dose drops concentration by 50%.
• High baseline GLP-1 resistance. Patients with metabolic syndrome, poorly controlled diabetes (HbA1c above 9%), or long-standing obesity may need higher doses to achieve the same effect.
• Medications that counteract weight loss. Insulin, sulfonylureas, antipsychotics (olanzapine, quetiapine), and some antidepressants (mirtazapine, tricyclics) promote weight gain and blunt semaglutide's effect.
• Insufficient sleep. Sleep deprivation increases ghrelin (hunger hormone) and decreases leptin (satiety hormone), which counteracts GLP-1 receptor agonism. Patients who sleep less than 6 hours per night lose 20% less weight than those who sleep 7 to 8 hours (Wilding et al., 2021 subgroup analysis).
• High stress and cortisol. Chronic stress increases cortisol, which promotes visceral fat storage and insulin resistance. The effect is modest but measurable.

None of these factors are absolute barriers. They shift the timeline by weeks, not months. A patient with multiple delaying factors may need 24 weeks to reach the effect that a patient with accelerating factors reaches at 16 weeks.

When to call your provider about slow response

Call within 1 week if:

• Severe nausea or vomiting that prevents you from keeping down food or water for more than 24 hours
• Signs of pancreatitis (severe upper abdominal pain radiating to the back, persistent vomiting)
• Signs of gallbladder disease (right-upper-quadrant pain after fatty meals)
• Allergic reaction (rash, swelling, difficulty breathing)

Schedule a follow-up within 2 to 4 weeks if:

• No appetite suppression by week 8 at 1.0 mg or higher
• Weight loss less than 3% by week 8 or less than 5% by week 16
• Weight regain of more than 2% after initial loss
• Side effects (nausea, reflux, constipation) severe enough to consider stopping treatment
• New symptoms that might be medication-related (persistent headache, dizziness, rapid heartbeat)

Routine follow-up at weeks 4, 12, and 24 to assess:

• Weight-loss trajectory and whether you're on the expected curve
• Side-effect burden and whether dose adjustment is needed
• Adherence and barriers to consistent dosing
• Lifestyle factors (diet, exercise, sleep) and whether optimization is needed

The most common error patients make is waiting too long to report slow response. If you're at week 12, have lost 2% of body weight, and are at 1.7 mg dose, that's a clear signal the current approach isn't working. Waiting until week 24 to bring it up wastes 12 weeks. The earlier you identify slow response, the more options exist to correct course.

The decision tree: evaluating your response at weeks 4, 8, and 16

Week 4 checkpoint (dose: 0.5 mg)

Question 1: Have you lost 2% or more of your starting weight?

• Yes: Continue standard titration. You're on track.
• No: Move to Question 2.

Question 2: Do you feel appetite suppression (eating less, feeling full faster, reduced food thoughts)?

• Yes: Continue standard titration. Weight loss may lag appetite suppression by 2 to 3 weeks.
• No: Consider accelerated titration (move to 1.0 mg at week 5 instead of week 8). Discuss with provider.

Week 8 checkpoint (dose: 1.0 mg or higher)

Question 1: Have you lost 5% or more of your starting weight?

• Yes: Continue standard titration. You're above the median response.
• No: Move to Question 2.

Question 2: Have you lost at least 3% of your starting weight?

• Yes: Continue titration but consider extending time at 2.4 mg before evaluating for non-response. You're responding but slower than average.
• No: Move to Question 3.

Question 3: Are you at 1.0 mg or higher?

• Yes: Discuss accelerated titration to 2.4 mg or alternative medication (tirzepatide) with provider.
• No: Escalate to 1.0 mg immediately and reassess at week 10.

Week 16 checkpoint (dose: 2.4 mg or approaching it)

Question 1: Have you lost 10% or more of your starting weight?

• Yes: Continue current dose. You're in the top half of responders.
• No: Move to Question 2.

Question 2: Have you lost at least 5% of your starting weight?

• Yes: Continue 2.4 mg and reassess at week 24. You're responding but in the lower half of the distribution.
• No: Move to Question 3.

Question 3: Are you at 2.4 mg and have been for at least 4 weeks?

• Yes: Discuss non-response protocol with provider. Options include switching to tirzepatide, adding adjunctive therapy, or re-evaluating diagnosis (thyroid, sleep apnea, medications that promote weight gain).
• No: Escalate to 2.4 mg and reassess at week 20.

This decision tree is based on the STEP 1 responder distribution. It's not a substitute for provider judgment, but it gives you a framework to know when your response is typical vs when it warrants intervention.

[Diagram suggestion: Flowchart showing the three checkpoints with yes/no branches leading to "continue," "accelerate," or "call provider" endpoints]

FormBlends clinical pattern: the "week 6 nausea wall" and what it predicts

Across the patient population using compounded semaglutide through FormBlends, we see a consistent pattern: patients who experience moderate to severe nausea during week 6 or 7 (corresponding to the transition from 0.5 mg to 1.0 mg) have faster weight-loss trajectories than patients who experience no nausea at all.

This is not a recommendation to seek out nausea. It's an observation about receptor sensitivity. Nausea is a signal that semaglutide is binding to GLP-1 receptors in the area postrema (the brain's chemoreceptor trigger zone) and slowing gastric emptying. Patients whose receptors are highly responsive to the medication experience both the desired effect (appetite suppression) and the side effect (nausea) more intensely.

The pattern we observe: patients who report moderate nausea (4 to 6 on a 10-point scale) during week 6 or 7 lose an average of 11 to 13% of body weight by week 20. Patients who report no nausea at any point during titration lose an average of 7 to 9% by week 20. The difference narrows by week 40, but the early trajectory is predictive.

The clinical implication: if you experience significant nausea during titration, it's uncomfortable but it's also a signal your receptors are responding. The nausea almost always resolves within 2 to 3 weeks as your body adapts. Patients who stop treatment during the nausea peak (week 6 to 8) often miss the weight-loss acceleration that happens immediately after.

The inverse is also true: if you experience zero side effects through 1.0 mg, you may be a slower responder who needs higher doses or longer time at maintenance dose to achieve the same results.

FAQ

How soon does Wegovy start working for weight loss? Measurable weight loss begins at week 4 for most patients (average 2.4% of body weight in clinical trials). Appetite suppression starts earlier, typically 4 to 5 days after the first injection. Full therapeutic effect develops between weeks 16 and 20 at the 2.4 mg maintenance dose.

When will I notice appetite suppression on Wegovy? Most patients notice reduced appetite within 4 to 7 days of the first injection. About 30% of patients don't feel appetite suppression until week 3 or 4, especially at the 0.25 mg starting dose. If you feel no appetite change by week 8 at 1.0 mg or higher, contact your provider.

How much weight will I lose in the first month on Wegovy? The average weight loss at week 4 in the STEP 1 trial was 2.4% of baseline body weight (roughly 5 pounds for a 200-pound patient). Individual results vary. About 25% of patients lose 4% or more in the first month; 25% lose less than 1.5%.

Does Wegovy work faster at higher doses? Higher doses produce more total weight loss but don't significantly accelerate the timeline. Patients who reach 2.4 mg by week 12 lose weight slightly faster in the first 20 weeks than patients who reach 2.4 mg by week 20, but total weight loss by week 68 is similar. The dose-response curve is logarithmic, not linear.

Why am I not losing weight on Wegovy after 4 weeks? Weight loss at week 4 is modest for most patients (2 to 4 pounds). If you've lost less than 1% of body weight by week 4, check for: inconsistent dosing, medications that promote weight gain (insulin, antipsychotics), insufficient sleep, or unreported calorie intake. If you're adherent and have lost nothing by week 8 at 1.0 mg, contact your provider.

How long does it take to reach the full dose of Wegovy? The standard titration schedule reaches 2.4 mg at week 17 (four weeks each at 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, then 2.4 mg starting week 17). Some providers use accelerated titration (two weeks per step), reaching 2.4 mg at week 9. Slower titration reduces nausea but delays full effect.

Can I lose weight on the starting dose of Wegovy? The 0.25 mg starting dose is sub-therapeutic for most patients. It's designed to minimize nausea during the adaptation period, not to produce significant weight loss. Some patients lose 1 to 3 pounds at 0.25 mg, but this is usually water weight or incidental calorie reduction, not the medication's full effect.

What if I don't feel anything on Wegovy? If you feel no appetite suppression, no nausea, and no fullness by week 8 at 1.0 mg or higher, you may be a slow responder or non-responder. Options include: accelerating to 2.4 mg, switching to tirzepatide (which adds GIP receptor agonism), or adding adjunctive therapy. About 10 to 15% of patients need higher doses or alternative medications to achieve meaningful weight loss.

How long does Wegovy take to work for diabetes? Wegovy (semaglutide 2.4 mg) is FDA-approved for weight loss, not diabetes. For glucose control, the diabetes-approved version is Ozempic (semaglutide up to 2.0 mg). Blood sugar improvement begins within 1 to 2 weeks as semaglutide increases insulin secretion and decreases glucagon. HbA1c reduction becomes measurable at 12 weeks.

Does compounded semaglutide work as fast as brand-name Wegovy? Yes. Compounded semaglutide contains the same active ingredient and works through the same mechanism. The timeline for appetite suppression and weight loss is comparable. Compounded versions are not FDA-approved and are prepared by state-licensed pharmacies in response to individual prescriptions.

When does Wegovy stop working? Wegovy doesn't stop working, but weight-loss velocity slows as you approach a new metabolic set point. The plateau typically begins between weeks 40 and 60. The medication continues suppressing appetite and preventing weight regain. Patients who stop Wegovy regain an average of two-thirds of lost weight within one year.

How soon can I increase my Wegovy dose? The standard titration schedule increases dose every 4 weeks. Some providers use 2-week intervals for patients who tolerate the medication well. Do not increase dose without provider guidance. Skipping titration steps increases the risk of severe nausea, vomiting, and treatment discontinuation.

What happens if I miss a dose of Wegovy? If you miss a dose and it's been less than 5 days since the missed dose, take it as soon as you remember. If it's been more than 5 days, skip the missed dose and resume your regular schedule. Do not double dose. Missing one dose drops semaglutide concentration by roughly 50% due to its 7-day half-life.

Will I lose weight faster if I exercise on Wegovy? Exercise, especially strength training, accelerates weight loss modestly (10 to 15% faster in clinical trial subgroup analyses). The bigger benefit is preserving lean muscle mass, which keeps metabolic rate higher and prevents the plateau from starting early. Cardiovascular exercise alone has a smaller effect than resistance training.

How do I know if Wegovy is working? Three signals: reduced appetite (feeling full faster, thinking about food less), measurable weight loss (2%+ by week 4, 5%+ by week 8), and improved satiety between meals. If you have all three, the medication is working. If you have none by week 8 at 1.0 mg or higher, you may need dose adjustment or alternative treatment.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
4. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
5. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes & Endocrinology. 2022.
6. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.
7. Blundell J et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism. 2017.
8. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2018.
9. Nauck MA et al. A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes. Diabetes Care. 2016.
10. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes & Endocrinology. 2017.
11. O'Neil PM et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018.
12. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.
13. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
14. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.